retatrutide triple agonist glp-1 gip glucagon ly3437943 Dr Retatrutide (LY3437943): Mechanism of Action

10.1016/j.cgh.2015.10.022 108 WatanabeT.NishioH.TanigawaT.YamagamiH.OkazakiH.WatanabeK.et al (2009)

You can't just tell people, change your lifestyle

However, it creates a regulatory exemption (under the FD&C Act) that allows compounders to manufacture the drug without an NDA

We know that at LEAST 13 different cancers (8) are associated with obesity including: Brain Kidney Breast Uterus Gallbladder Stomach Liver Ovaries Pancreas Thyroid Meningioma Multiple myeloma Colon And obesity doesnt just stop there in terms of its negative impact on your health

These comparisons require appropriate caveats

With the scope expanding and more employers increasing their total annual spend providing GLP-1 coverage, employers who can get ahead of the cost trend may find themselves in a more prepared position